Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - PEGylated (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Yang BB, Kido A: Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011 May 1;50(5):295-306. doi: 10.2165/11586040-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21456630 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...y/drugbank/patent
| |
http://linked.open...outeOfElimination
| - Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalization of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells. Pegylation of filgrastim renders renal clearance insignificant, which was demonstrated in bilaterally nephrectomized rats and confirmed in subjects with renal impairment. As a result, the neutrophil-mediated clearance is the predominant elimination pathway for pegfilgrastim. During chemotherapy-induced neutropenia, the clearance of pegfilgrastim is significantly reduced and the concentration of pegfilgrastim is sustained until onset of neutrophil recovery. (en)
|
http://linked.open.../drugbank/synonym
| - Lenograstim (en)
- G-CSF (en)
- Granulocyte colony-stimulating factor precursor (en)
- Pluripoietin (en)
- N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene) (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...nk/Hydrophobicity
| |
http://linked.open...Isoelectric-Point
| |
http://linked.open...ank/Melting-Point
| |